AI Analysis | Feedback

• An emerging Alexion Pharmaceuticals focused on rare liver diseases.
• A biotech company specializing in rare cholestatic liver conditions, much like an Ultragenyx Pharmaceutical.
• Like Sarepta Therapeutics, but instead of neuromuscular disorders, they target rare liver diseases.

AI Analysis | Feedback

• LIVMARLI (maralixibat): An oral medication approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS).
• CHENODAL (chenodiol): A bile acid replacement therapy approved for the treatment of cerebrotendinous xanthomatosis (CTX).

AI Analysis | Feedback

Mirum Pharmaceuticals (MIRM) sells primarily to other companies, specifically pharmaceutical wholesalers, rather than directly to individuals. As stated in their financial filings, substantially all of their gross product sales are made to three major wholesalers. These companies then distribute Mirum's products to pharmacies, hospitals, and other healthcare providers.

The major customers for Mirum Pharmaceuticals are:

• AmerisourceBergen Corporation (Symbol: ABC)
• Cardinal Health, Inc. (Symbol: CAH)
• McKesson Corporation (Symbol: MCK)

AI Analysis | Feedback

• Hovione Interamericana, S.A.
• Almac Pharma Services Ltd.
• Curia Global, Inc.
• Dishman Carbogen Amcis Ltd. (Symbol: DCAL.NS)
• Accu-Break Pharmaceuticals, Inc.

AI Analysis | Feedback

Chris Peetz Chief Executive Officer

Chris Peetz is the Co-Founder, President, and Chief Executive Officer of Mirum Pharmaceuticals, appointed in March 2019. He served as an Entrepreneur-in-Residence on the Frazier Life Sciences team and founded Flashlight Therapeutics. Previously, Mr. Peetz was the Chief Financial Officer and Head of Corporate Development at Tobira Therapeutics, a Frazier portfolio company, where he led the company's efforts to go public, expand its pipeline, and ultimately oversaw its acquisition by Allergan for up to $1.7 billion. His earlier career includes business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals, and Abgenix. Mr. Peetz holds a B.S.B.A. from Washington University in St. Louis and an M.B.A. from the Stanford Graduate School of Business.

Eric Bjerkholt Chief Financial Officer

Eric Bjerkholt joined Mirum Pharmaceuticals as Chief Financial Officer in September 2023. Prior to Mirum, he served as CFO at Chinook Therapeutics, Inc., overseeing financial reporting, planning, budgeting, internal controls, investor relations, facilities, and information technology. Before Chinook, he was CFO at Aimmune Therapeutics, Inc. Mr. Bjerkholt's experience also includes roles at Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. He spent nearly a decade in healthcare investment banking at J.P. Morgan & Company, Inc. Mr. Bjerkholt is currently a board member of CalciMedica, Inc., Cerus Corporation, and Surrozen, Inc. He earned an MBA from Harvard Business School and a Cand. Oecon degree from the University of Oslo.

Peter Radovich President & Chief Operating Officer

Peter Radovich joined Mirum in April 2020 as Chief Operating Officer, bringing over 20 years of operational experience in the biopharmaceutical industry. Before Mirum, he was the Executive Vice President, Operations at Global Blood Therapeutics (GBT) from 2014 to 2020, where he was responsible for technical operations, supply chain, program management and leadership, quality assurance, and commercial strategy and analytics. From 2006 to 2014, Mr. Radovich held various roles at Onyx Pharmaceuticals, Inc. (now Amgen, Inc.), including Vice President, Program Leadership, and positions in commercial and corporate strategy.

Joanne Quan, M.D. Chief Medical Officer

Joanne Quan, M.D., serves as the Chief Medical Officer at Mirum Pharmaceuticals. She is a member of the company's leadership team and participates in investor calls, discussing clinical programs and updates.

Lara Longpre Chief Development Officer

Lara Longpre is the Chief Development Officer at Mirum Pharmaceuticals. She has over 19 years of drug development and operations experience, holding leadership and senior roles in biotechnology companies and contract research organizations (CROs).

AI Analysis | Feedback

The key risks to Mirum Pharmaceuticals (MIRM) are primarily centered around its drug development pipeline, financial performance, and market dynamics for its approved products.

1. Clinical Development and Commercialization Risks for Pipeline Candidates: A significant risk for Mirum Pharmaceuticals is the successful development and commercialization of its pipeline candidates. The company has several investigational medicines, including volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), MRM-3379 for Fragile X syndrome, and the recently acquired brelovitug for chronic hepatitis delta virus (HDV) infection. The potential upside for Mirum Pharmaceuticals is heavily reliant on the success of these late-stage pipeline assets in pivotal trials. Any setbacks, such as trial failures, delays in regulatory approval, or an inability to effectively commercialize these products, could materially and adversely affect the company's financial condition and stock price. For example, the upside case for Mirum could "unravel if volixibat stumbles in pivotal trials". The clinical development and commercialization of brelovitug alone are expected to require approximately $250 million over the next two years.
2. Financial Position and Path to Profitability: Mirum Pharmaceuticals is currently operating at a loss and is projected to remain unprofitable until at least 2027. While the company anticipates becoming cash flow positive by the end of fiscal year 2025, it carries a notable amount of debt, with approximately $308.9 million at June 2025. Although its cash and near-term receivables are substantial, liabilities due within a year and beyond slightly outweigh them. Continued heavy investment in research and development and strategic acquisitions necessitates a strong financial position, and a failure to achieve sustained profitability or manage its debt effectively could pose a significant risk.
3. Competition, Pricing, and Reimbursement Pressures: Even for Mirum's approved medicines like LIVMARLI (maralixibat), the company faces risks from intensifying competition, pricing challenges, and reimbursement pressures. These external market factors could lead to an underperformance of existing products and impact revenue growth. The rare disease market, while offering high unmet medical need, is also subject to scrutiny over drug pricing and access, which could constrain the commercial success of Mirum's portfolio.

AI Analysis | Feedback

The primary clear emerging threat to Mirum Pharmaceuticals stems from direct competition in the rare cholestatic liver disease market, specifically from **Bylvay (odevixibat)**, developed by Ipsen (which acquired Albireo Pharma). Both LIVMARLI (maralixibat) from Mirum and Bylvay are ileal bile acid transporter (IBAT) inhibitors, targeting similar patient populations and indications.

• Bylvay is approved in the European Union for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS), directly competing with Mirum's LIVMARLI in this market and indication.
• Bylvay is approved in both the United States and the European Union for the treatment of progressive familial intrahepatic cholestasis (PFIC). This creates a direct competitive threat to Mirum as it seeks to expand LIVMARLI's label into the PFIC indication.

This head-to-head competition from a similarly acting drug by a well-capitalized competitor presents an ongoing challenge to Mirum's market share, pricing leverage, and ability to expand its product into new indications.

AI Analysis | Feedback

Mirum Pharmaceuticals' main products and their addressable markets are as follows:

• Volixibat: The worldwide total addressable market for volixibat in Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis (PBC) is estimated to be more than $1 billion. Additionally, the addressable market for Volixibat in Fragile X Syndrome (FXS) is also more than $1 billion.
• Livmarli (maralixibat): While a precise addressable market size in dollar figures is not explicitly stated, Livmarli is projected to generate $9.07 billion in sales globally by 2029. In the U.S., the addressable patient population for Alagille Syndrome (ALGS) is over 500 prevalent patients plus newly diagnosed individuals. For Progressive Familial Intrahepatic Cholestasis (PFIC) in the U.S., there are approximately 350 newly diagnosed patients per year.
• Cholbam (cholic acid): The U.S. market has an estimated 200 to 300 patients who are current candidates for therapy. The peak revenue opportunity for Cholbam is estimated at approximately $90 million per annum.
• Chenodal (chenodiol): While no specific addressable market size is provided for Chenodal alone, the potential peak revenues for Cholbam and Chenodal combined are around $450 million.

AI Analysis | Feedback

AI Analysis | Feedback

Share Issuance

• In August 2022, Mirum Pharmaceuticals completed a public offering of 4,000,000 shares of common stock at $23.00 per share, generating gross proceeds of $92 million. The underwriters fully exercised their option to purchase an additional 521,739 shares.
• Mirum Pharmaceuticals registered an Employee Benefit Plan on September 9, 2025.
• As of June 30, 2025, the company had not issued any securities under its 2023 Sales Agreement.

Outbound Investments

• In August 2023, Mirum Pharmaceuticals acquired the bile acid products Cholbam and Ctexli from Travere Therapeutics.

Capital Expenditures

• Mirum Pharmaceuticals reported capital expenditures of $0.23 million in 2020, $19.02 million in 2021, $0.28 million in 2022, $20.11 million in 2023, and $20.99 million in 2024.
• Projected capital expenditures are $103 million for 2025, $105 million for 2026, $108 million for 2027, $110 million for 2028, and $114 million for 2029.